A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

This study is checking whether two formulations of a PARP inhibitor drug (olaparib) — BR2022 and BR2022-1 — are absorbed and processed by the body in the same way (called bioequivalence), in women with advanced ovarian cancer linked to a BRCA gene mutation who are already being treated with stable-dose olaparib. **You may be eligible if...** - You are a female aged 19 to 74 - You have advanced ovarian, fallopian tube, or primary peritoneal cancer with a BRCA gene mutation (inherited or acquired) - You have already been taking olaparib at a stable dose for more than 3 months **You may NOT be eligible if...** - You have a history of severe allergic reactions to similar drugs - You have gastrointestinal conditions (such as Crohn's disease, reflux disease, or stomach ulcers) or prior GI surgery that could affect drug absorption - You are pregnant, possibly pregnant, or breastfeeding Talk to your doctor to see if this trial is right for you.